Objective. To determine whether inflammatory markers prospectively predict depressive symptom severity 12 months later in heart failure (HF) patients. Methods. In 30 HF patients we assessed depressive symptom severity by the Beck depression inventory (BDI) at baseline as well as 12 months later. We measured circulating levels of the soluble intercellular adhesion molecule (sICAM)-1, the cytokine interleukin (IL)-6 and the acute phase protein C-reactive protein (CRP) at baseline assessment. Results. sICAM-1 (r = .38, p = .045) but not CRP or IL-6 correlated with BDI scores 12 months later. Hierarchical linear regression analysis revealed that independent of baseline BDI assessment, cardiovascular risk factors, indicators of HF disease severity, and medication intake, sICAM-1 significantly predicted BDI scores 12 months later. sICAM-1 independently explained between 7% (b = .26, p = .040) and 10% (b = .35, p = .045) of the total variance in BDI scores 12 months later. Conclusion. The findings from this exploratory analysis suggest that the adhesion molecule sICAM-1 is an independent predictor of depressive symptoms 12 months later in HF patients. Our prospective findings support the suggested role for inflammation in increasing future depressive symptom severity and extend this linkage for the first time to HF.
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Introduction
A recent hypothesis posits that inflammation can lead to depression and depressive symptoms in vulnerable patients (Dantzer et al., 2008) . Heart failure (HF) is a major public health concern associated with both increased incidence of depressive symptoms and clinical depression as well as elevated pro-inflammatory activities indicated by levels of adhesion molecules or inflammatory cytokines (Mari et al., 2002; Parissis et al., 2005; Rutledge et al., 2006; York et al., 2008) . Indeed, we and others report cross-sectional associations between inflammation and depressive symptoms or clinical depression in HF patients (Moorman et al., 2007; Parissis et al., 2004; Redwine et al., 2007) . However, although elevated biomarkers of inflammation were shown to precede the onset of depressed mood in an aged non-HF population (van den Biggelaar et al., 2007) , a prospective relationship between inflammation and depressive symptoms has not yet been studied in HF.
The purpose of this exploratory study was to determine whether different types of inflammatory markers (i.e. an adhesion molecule, an inflammatory cytokine, and an acute phase protein) prospectively predict depressive symptom severity 12 months later in HF patients. We controlled for a variety of potential confounders including cardiovascular risk factors, indicators of HF severity, and medication intake.
Methods

Study participants
The study sample consisted of 30 patients diagnosed with HF. Patients were recruited from the San Diego Veterans Affairs Medical Center and the University of California, San Diego Medical Center Heart Failure Program as part of a larger study on associations between depression, cellular adhesion and inflammation.
Inclusion criteria included age between 30 and 85 years, NYHA classes II through IV, symptoms of HF for at least 3 months which have been optimally treated with beta-blockers, diuretics and ACE inhibitors, and systolic dysfunction defined by an ejection fraction 645% or diastolic dysfunction, hypertension <180/110 mm Hg, and 
